Dose-dependent reduction of hazardous alcohol use in a placebo-controlled trial of naltrexone for smoking cessation.
The opiate antagonist naltrexone (Ntx) has demonstrated efficacy in the treatment of alcohol dependence and as a component of treatment to reduce heavy drinking. At present, there are no published dose-ranging clinical trials of the oral preparation for treatment of problem drinking. The present study evaluated the effects of Ntx on alcohol use among the subset of hazardous drinkers (n=102) who participated in a placebo-controlled, dose-ranging trial of oral Ntx (25-mg, 50-mg and 100-mg doses) combined with open-label transdermal nicotine patch for enhancing smoking cessation. On the primary outcome--no hazardous drinking (drinking that exceeded weekly or daily limits) during treatment--25 mg and 50 mg Ntx were superior to placebo (each p<0.05). These findings remained after controlling for baseline predictors or smoking abstinence during treatment. Time to remission of hazardous drinking was examined as a secondary outcome with definitions of hazardous drinking based on weekly limits, daily limits and the combination of weekly and daily limits and the results were consistent with the primary findings. In conclusion, the findings suggest that Ntx can reduce the risk of hazardous drinking in smokers who are not seeking or receiving alcohol treatment, providing strong evidence for the pharmacological effects of Ntx on drinking. This effect appears to favour lower doses that may be better tolerated and less expensive than the higher 100-mg dose. Given its efficacy and favourable side-effect profile, the 25-mg dose should be considered for future studies of combination therapy.
O'Malley
Stephanie S
SS
Department of Psychiatry, Yale University School of Medicine, New Haven, CT 06519, USA. stephanie.omalley@yale.edu
Krishnan-Sarin
Suchitra
S
McKee
Sherry A
SA
Leeman
Robert F
RF
Cooney
Ned L
NL
Meandzija
Boris
B
Wu
Ran
R
Makuch
Robert W
RW
D000328:Adult; D000428:Alcohol Drinking / Q000188:drug therapy* / Q000523:psychology; D000437:Alcoholism / Q000188:drug therapy / Q000523:psychology; D004305:Dose-Response Relationship, Drug; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009271:Naltrexone / Q000008:administration & dosage*; D012907:Smoking / Q000188:drug therapy* / Q000523:psychology; D016540:Smoking Cessation / Q000379:methods*
D009271:Naltrexone
Neuropsychopharmacology. 2001 Oct;25(4):537-47
11557167
Behav Pharmacol. 1995 Jun;6(4):386-394
11224347
Psychopharmacology (Berl). 2006 May;186(1):54-63
16565827
J Gen Intern Med. 1997 May;12(5):274-83
9159696
Arch Gen Psychiatry. 1992 Nov;49(11):876-80
1345133
Biol Psychiatry. 2004 Feb 1;55(3):255-62
14744466
Arch Gen Psychiatry. 1992 Nov;49(11):881-7
1444726
JAMA. 2005 Apr 6;293(13):1617-25
15811981
J Clin Psychopharmacol. 2003 Jun;23(3):294-304
12826991
Psychopharmacology (Berl). 2008 Feb;196(2):189-200
17912500
Alcohol Clin Exp Res. 2000 Sep;24(9):1385-91
11003204
Psychopharmacology (Berl). 2002 Feb;160(1):19-29
11862370
Biol Psychiatry. 2007 Sep 15;62(6):694-7
17336941
JAMA. 2006 May 3;295(17):2003-17
16670409
J Clin Psychopharmacol. 2007 Oct;27(5):507-12
17873686
Alcohol Clin Exp Res. 2008 Jan;32(1):58-66
18028530
J Clin Psychopharmacol. 2007 Feb;27(1):112-5
17224736
Psychopharmacology (Berl). 2004 Apr;173(1-2):32-40
14722705
Arch Intern Med. 2006 Mar 27;166(6):667-74
16567607
Neuropsychopharmacology. 2000 May;22(5):480-92
10731623
Br J Addict. 1991 Sep;86(9):1119-27
1932883
Arch Intern Med. 1999 Aug 9-23;159(15):1681-9
10448769
Drug Alcohol Depend. 1997 Aug 25;47(2):109-16
9298332
Cochrane Database Syst Rev. 2005 Jan 25;(1):CD001867
15674887
J Clin Psychopharmacol. 2006 Dec;26(6):610-25
17110818